AI-generated · cited to primary sources · not investment advice
Apollo Hospitals (508869) Jun 2025 Filing Analysis
Does management do what it says?
Digital losses narrowed to INR 71 crore in Q2 FY26 from INR 101 crore in Q2 FY25, showing significant progress toward the breakeven target. (3 in progress across 3 tracked commitments)
“Target to achieve EBITDA breakeven for digital business in next 4 quarters”
See the full cited Management analysis of Apollo Hospitals
How durable is the business?
Apollo HealthCo is being restructured through a composite scheme of arrangement to demerge its omnichannel pharmacy distribution and digital health platform into a new listed entity ('New Co'). This entity will also merge with Keimed to create India's largest pharma distributor. The proforma revenue for this combined segment is estimated at INR 16,267 Cr for FY25, with a target to reach INR 25,000 Cr by FY27. (1 shifted)
“Creates a formidable Listed Omni channel Pharmacy distribution and Digital health platform leader in India with a scale of INR ~16.3k Cr (~US$ 1.9 bn) in Revenues in FY25 with stated plans to achieve ~ Rs25k Cr (~US$ 3 bn) Revenue run-rate estimated by end FY27”
See the full cited Business Model analysis of Apollo Hospitals
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.